Notably, significant overexpression of YTHDF2 has been verified in cisplatin-resistant ICC tissues, and been demonstrated to promote cell proliferation, inhibit apoptosis, reduce G0/G1 phase arrest, and confer resistance to cisplatin in ICC cells. Here, YTHDF2 is linked to intrahepatic cholangiocarcinoma.